Latest news and press releases about Celularity Inc. (CELU): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.
Price
| Price | $1.29 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.73 |
| EV / EBITDA | -0.91 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 411.46% |
| Return on Invested Capital | -151.11% |
| Return on Assets | -85.45% |
| Gross Margin | 76.04% |
| Operating Margin | -230.92% |
| Net Margin | -345.44% |
Related companies: ANVS · ATNM · BCAB · BTAI · FGEN · GBIO · KZR
Explore sector: Healthcare · Biotechnology
More sections of CELU: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks